Advantage Manocept in advancing therapeutic targeting/treatment over mannose only use | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  40304 of 40750  at  9/4/2023 3:03:05 PM  by

moneyonomics

The following message was updated on 9/4/2023 6:12:10 PM.

Advantage Manocept in advancing therapeutic targeting/treatment over mannose only use

  
 2023 pre proof  out of China on Biological Function, Regulatory Mechanism, and Clinical Application of Mannose in Cancer  points out 68Ga-DOTA-Manocept (ref 237) as well as Lymphoseek (ref 191) progress along with many others for cancer and other therapeutic. The two main themes in  pre proof :

 

1) Mannose clinical applications and their reported progress on mannose as a therapeutic and as a backbone to transport payloads have been greatly neglected

 

2) The draft extensively discusses mannose as a therapeutic. In many of the Navidea updates on the development of Manocept, it has been highlighted below that results with a payload attached to the Manocept backbone provide much stronger therapeutic results than mannose backbone alone, The treatment importance and significance of the  point that mannose only therapeutics are disadvantaged to Manocept transporting a payload should be a strategic  advantage to future funders

 

I have also provided a 2022 studies (China) that point to several of the same mannose concepts/opportunities.


 
MT Website
 
 
 
 

Biological Function, Regulatory Mechanism, and Clinical Application of Mannose in Cancer

 For educational purposes only.